US69833W1071 - Common Stock - After market: 1.5 +0.07 (+4.9%)
NASDAQ:PBLA (1/27/2023, 7:27:00 PM)-0.18 (-11.18%)
GICS Sector | Health Care | ||
GICS Industry | Biotechnology |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-10 2022-11-10/amc | Earnings (Next) | 03-22 2023-03-22 |
Ins Owners | 85.76% | Inst Owners | N/A |
Market Cap | 1.13M | Shares | 792.80K |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 80 |
IPO | 07-29 2014-07-29 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Panbela Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waconia, Minnesota and currently employs 4 full-time employees. The company went IPO on 2014-07-29. Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing disruptive therapeutics for the treatment of patients with cancer. Its primary focus is on the treatment of patients with pancreatic cancer. Its lead product candidate, SBP-101, is a polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma, ovarian cancer and other tumors. The firm is conducting Phase Ia/Ib study of the safety, tolerability and pharmacokinetics of SBP-101 when administered in combination with gemcitabine and nab-paclitaxel.
PANBELA THERAPEUTICS INC
712 Vista Blvd # 305
Waconia MINNESOTA 55387
P: 19524791196.0
CEO: Jennifer K. Simpson
Employees: 4
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.
Panbela Therapeutics (PBLA) said Thursday it priced public offering of 6,675,000 shares of its common stock and warrants to purchase up to 13,350,000 shares.
Here you can normally see the latest stock twits on PBLA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: